AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

Amsterdam-listed shares in ASML (ASML.AS, ASML) slid more than 7% on Wednesday morning, after the chipmaking equipment supplier narrowed its guidance and offered a cautious outlook for 2026. In ...

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

The 24-year study of more than 1.2 million children in Denmark found that aluminum exposure didn't raise the risk of autism, asthma, or other chronic diseases. Other science and research news is on ...